NCT03406871 - Regorafenib and Nivolumab Simultaneous Combination Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions

Advanced and Metastatic Solid Tumor

Interventions

DRUG

Regorafenib

One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.

DRUG

Nivolumab

One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.

Trial Locations (1)

277-8577

NationalCCHE, Kashiwa